Skip to main content
. Author manuscript; available in PMC: 2010 Nov 22.
Published in final edited form as: Clin Cancer Res. 2009 Oct 6;15(20):6367–6377. doi: 10.1158/1078-0432.CCR-09-0910

Fig. 4.

Fig. 4

Effect of different doses and schedules of administration on the efficacy of oral BSI-401 as single agent. Forty athymic mice bearing orthotopic COLO357FG pancreatic tumors were randomly allocated (n= 5) to be treated with oral BSI-401 as indicated, gemcitabine (25 mpk BIW×4), or the oral vehicle for BSI-401 as control. A, B, Tumor volume following treatment, quantified as the sum of all detected photons within the region of the tumor per second. Means and SE are shown. * P< 0.05 treatment versus control by one-way analysis of variance and Dunnett’s multiple comparison post test. C, Survival curves following treatment. Mice were sacrificed by carbon dioxide inhalation when evidence of advanced bulky disease was present. The day of sacrifice was considered the day of death for survival evaluation.